플러스100%마이너스

  • 화면크기
통합검색

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Chinese herbal medicine for resistant hypertension: a systematic review.

Authors

Xiong X, Li X, Zhang Y, Wang J.

Journal

BMJ Open.

Year

2015

Vol (Issue)

5(1)

Page

e005355.

doi

10.1136/bmjopen-2014-005355.

PMID

25636788

Url

http://www.ncbi.nlm.nih.gov/pubmed/25636788

MeSH

Antihypertensive Agents/therapeutic use*
Blood Pressure/drug effects*
Drugs, Chinese Herbal/therapeutic use*
Humans
Hypertension/drug therapy*
Treatment Outcome

Keywords

Chinese herbal medicine; resistant hypertension; systematic review

한글 키워드

중약학; 저항성 고혈압; 체계적 문헌고찰

KMCRIC summary and commentary

없음

Korean Study

Abstract

OBJECTIVES:
This study aimed to summarise the current evidence from randomised control trials (RCTs) concerning treatment of patients with resistant hypertension with Chinese herbal medicine (CHM).

DESIGN:
Seven databases, including the Cochrane Library, PubMed, EMBASE, CNKI, VIP, CBM and Wanfang, were systematically searched from their inception to March 2014 for RCTs investigating treatment of resistant hypertension in which CHM was used either as a monotherapy or in combination with conventional medicine versus placebo, no intervention or conventional medicine.

RESULTS:
Five trials containing 446 hypertensive patients were identified. The methodological quality of most trials was evaluated as generally low. All included trials compared CHM plus antihypertensive drugs with antihypertensive drugs alone for resistant hypertension. Formulations of CHM included tablet, decoction and injection. It was found that, compared with antihypertensive drugs alone, CHM (tablet) plus antihypertensive drugs resulted in clinically, but not statistically, significant reductions in systolic blood pressure (SBP; weighted mean difference (WMD)=-10.32 mm Hg; 95% CI -21.10 to 0.46; p=0.06) and diastolic blood pressure (DBP; WMD=-3.30 mm Hg; 95% CI -7.66 to 1.06; p=0.14). CHM (decoction) plus antihypertensive drugs also produced a clinically meaningful, but not statistically significant, reduction in SBP (WMD=-12.56 mm Hg; 95% CI -26.83 to 1.71; p=0.08), and did significantly decrease DBP (WMD=-7.89 mm Hg; 95% CI -11.74 to -4.04; p<0.0001). There were no significant differences in SBP (WMD=-3.50 mm Hg; 95% CI -8.95 to 1.95; p=0.21) and DBP (WMD=1.00 mm Hg; 95% CI -1.39 to 3.39; p=0.41) between CHM (injection) plus the antihypertensive drugs group and antihypertensive drugs alone. The safety of CHM remained uncertain.

CONCLUSIONS:
No definite conclusions about the effectiveness and safety of CHM for resistant hypertension could be drawn. More rigorously designed trials are warranted.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

국문초록

Language

영어

첨부파일